Novo Nordisk A/S — China drug registrations and re-registration deadlines
34 certificates in the NMPA overseas-manufactured drug database (境外生产药品库), snapshot 2026-06-28. Earliest re-registration deadline: 2027-01-18.
| Approval number | Product | Certificate expires | Re-registration deadline (Art. 82) |
|---|---|---|---|
| 国药准字SJ20170044 | Tresiba 德谷胰岛素注射液 | 2027-07-18 | 2027-01-18 |
| 国药准字SJ20170045 | Tresiba 德谷胰岛素注射液 | 2027-07-18 | 2027-01-18 |
| 国药准字SJ20201025 | Novolin R 人胰岛素注射液 | 2027-08-21 | 2027-02-21 |
| 国药准字SJ20201017 | Novolin N 精蛋白人胰岛素注射液 | 2027-10-13 | 2027-04-13 |
| 国药准字SJ20201004 | Novolin 30R 精蛋白人胰岛素混合注射液(30R) | 2027-11-08 | 2027-05-08 |
| 国药准字SJ20240005 | Rybelsus 司美格鲁肽片 | 2029-01-22 | 2028-07-22 |
| 国药准字SJ20240006 | Rybelsus 司美格鲁肽片 | 2029-01-22 | 2028-07-22 |
| 国药准字SJ20190027 | Ryzodeg 德谷门冬双胰岛素注射液 | 2029-04-09 | 2028-10-09 |
| 国药准字SJ20190028 | Ryzodeg 德谷门冬双胰岛素注射液 | 2029-04-09 | 2028-10-09 |
| 国药准字SJ20150061 | NovoSeven 注射用重组人凝血因子Ⅶa | 2029-05-28 | 2028-11-28 |
| 国药准字SJ20150062 | NovoSeven 注射用重组人凝血因子Ⅶa | 2029-05-28 | 2028-11-28 |
| 国药准字SJ20150063 | NovoSeven 注射用重组人凝血因子Ⅶa | 2029-05-28 | 2028-11-28 |
| 国药准字SJ20240017 | Awiqli 依柯胰岛素注射液 | 2029-06-17 | 2028-12-17 |
| 国药准字SJ20240018 | Awiqli 依柯胰岛素注射液 | 2029-06-17 | 2028-12-17 |
| 国药准字SJ20240019 | Awiqli 依柯胰岛素注射液 | 2029-06-17 | 2028-12-17 |
| 国药准字SJ20240020 | Wegovy 司美格鲁肽注射液 | 2029-06-17 | 2028-12-17 |
| 国药准字SJ20240021 | Wegovy 司美格鲁肽注射液 | 2029-06-17 | 2028-12-17 |
| 国药准字SJ20240022 | Wegovy 司美格鲁肽注射液 | 2029-06-17 | 2028-12-17 |
| 国药准字SJ20240023 | Wegovy 司美格鲁肽注射液 | 2029-06-17 | 2028-12-17 |
| 国药准字SJ20240024 | Wegovy 司美格鲁肽注射液 | 2029-06-17 | 2028-12-17 |
| 国药准字SJ20240027 | Esperoct 注射用培妥罗凝血素α | 2029-06-27 | 2028-12-27 |
| 国药准字SJ20240028 | Esperoct 注射用培妥罗凝血素α | 2029-06-27 | 2028-12-27 |
| 国药准字SJ20240042 | Esperoct 注射用培妥罗凝血素α | 2029-09-09 | 2029-03-09 |
| 国药准字SJ20240043 | Esperoct 注射用培妥罗凝血素α | 2029-09-09 | 2029-03-09 |
| 国药准字SJ20160004 | Victoza 利拉鲁肽注射液 | 2030-03-02 | 2029-09-02 |
| 国药准字SJ20200027 | NovoEight 注射用重组人凝血因子VIII | 2030-11-04 | 2030-05-04 |
| 国药准字SJ20200028 | NovoEight 注射用重组人凝血因子VIII | 2030-11-04 | 2030-05-04 |
| 国药准字SJ20200029 | NovoEight 注射用重组人凝血因子VIII | 2030-11-04 | 2030-05-04 |
| 国药准字SJ20200030 | NovoEight 注射用重组人凝血因子VIII | 2030-11-04 | 2030-05-04 |
| 国药准字SJ20250030 | Sogroya 帕西生长激素注射液 | 2030-12-21 | 2030-06-21 |
| 国药准字SJ20250031 | Sogroya 帕西生长激素注射液 | 2030-12-21 | 2030-06-21 |
| 国药准字SJ20260018 | Kyinsu 依柯胰岛素司美格鲁肽注射液 | 2031-03-02 | 2030-09-02 |
| 国药准字SJ20260019 | Kyinsu 依柯胰岛素司美格鲁肽注射液 | 2031-03-02 | 2030-09-02 |
| 国药准字SJ20260020 | Kyinsu 依柯胰岛素司美格鲁肽注射液 | 2031-03-02 | 2030-09-02 |
Under the Provisions for Drug Registration (药品注册管理办法) Art. 82, an application to renew an overseas-manufactured drug registration is filed with the Center for Drug Evaluation no later than 6 months before the certificate expires; the filing line column is that arithmetic applied to the expiry cell. Art. 84(1): a certificate with no application by expiry is not re-registered and is cancelled at expiry. Every figure is taken from the public NMPA database as of 2026-06-28, or computed from it. Registration data changes; the NMPA portal governs. This page states no view on whether any of these products' Domestic Responsible Person (境内责任人) arrangements meet NMPA Announcement No. 137 — that cannot be determined from a public entry.